CRISPR Market Overview

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology, notably CRISPR-Cas9, functions as molecular scissors that precisely edit DNA.

Guided by RNA sequences, CRISPR-Cas9 targets specific genetic locations, offering unprecedented capabilities in gene editing for medical treatments, agricultural improvements, and biological research.

Despite ethical considerations and regulatory challenges, CRISPR’s rapid evolution continues to expand its applications. Including promising advancements in personalized medicine and biotechnology.

Ongoing research and development aim to harness its full potential while addressing safety and ethical concerns. Positioning CRISPR as a pivotal tool in shaping the future of genetic engineering and beyond.

Market Drivers

Several key factors drive the global CRISPR market. Increasing demand for precise gene-editing tools in biomedical research and therapies is a major growth driver.

Expanding investments in biotechnology and pharmaceuticals, alongside broader applications in drug discovery, also contribute to market growth. Innovations in CRISPR technology variants like base editing and CRISPR interference enhance versatility and commercial potential.

Supportive regulatory frameworks and collaborative efforts among academia, biotech firms, and pharmaceuticals further accelerate market dynamics.

Overall, these factors highlight CRISPR’s significant role in advancing healthcare and biotechnology through innovation and transformative capabilities.

Market Size

The global CRISPR technology market is projected to reach approximately USD 15.0 billion by 2033, up from USD 3.2 billion in 2023. With a compound annual growth rate (CAGR) of 16.7% from 2024 to 2033.

List of Major Companies

These are the top ten companies operating in the CRISPR Market:


Company Overview

Establishment Year 1888
Headquarter Green Oaks, Illinois, U.S.
Key Management Robert B. Ford (Chairman & CEO)
Revenue (US$ Bn) $ 40.1 Billion (2023)
Headcount ~ 114,000 (2023)

About Abbott Laboratories

Abbott Laboratories has been actively advancing in the CRISPR technology sector, focusing on gene editing applications to treat genetic disorders.

Recent strategic initiatives include increased investments in R&D and new facility setups to boost CRISPR research and production capabilities.

In 2023, Abbott reported significant growth in diagnostics and molecular divisions, driven by CRISPR-based innovations in gene editing and diagnostics.

The company is also expanding CRISPR applications through collaborations, especially in in vivo therapies and precision medicine.

Ongoing clinical trials and product developments aim to harness CRISPR’s therapeutic potential effectively.

Geographical Presence

Abbott Laboratories, based in Abbott Park, Illinois, is a global healthcare leader with a strong presence across key markets.

In North America, it operates extensively in the US and Canada, with multiple facilities. In Europe, Abbott has significant operations in the UK, Germany, France, Italy, and Spain, supported by local manufacturing and research.

In Asia-Pacific, including Japan, China, India, and Australia, Abbott addresses diverse healthcare needs through strategic investments.

In Latin America, Abbott expands its pharmaceuticals, nutrition, and medical devices businesses in Brazil, Mexico, Argentina, and Chile. Globally, Abbott serves over 160 countries, ensuring broad access to its healthcare solutions.

Recent Developments

  • In April 2024, Abbott’s FDA approval of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System represented a significant leap forward in treating severe limb-threatening ischemia below the knee.
  • In January 2024, Abbott introduced its new PROTALITY™ brand, featuring a high-protein nutrition shake aimed at adults seeking weight loss while preserving muscle mass and overall nutrition.


Company Overview

Establishment Year 1891
Headquarter Rahway, New Jersey, U.S.
Key Management Robert M. Davis (Chairman, President and CEO)
Revenue (US$ Bn) $ 60.1 B (2023)
Headcount ~ 72,000 (2023)

About Merck

Merck & Co., Inc. has actively expanded its involvement in CRISPR technology, aiming to enhance genome-editing capabilities for therapeutic advancements.

Recently, Merck entered strategic collaborations and licensing deals with PanCELLa and Takara Bio USA in January 2024 to strengthen CRISPR integration and vector technologies for cell engineering services.

Additionally, Merck acquired Harpoon Therapeutics for $656 million early in 2024, emphasizing its commitment to bolstering its oncology pipeline through CRISPR technology for innovative cancer treatments.

These initiatives highlight Merck’s focus on advancing biomedical research and development, particularly in personalized medical solutions.

Geographical Presence

Merck & Co., Inc., based in Kenilworth, New Jersey, operates a robust global pharmaceutical network spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.

In North America, it maintains a strong presence in the US and Canada, with extensive facilities and research hubs.

Across Europe, it is notably established in countries like Germany and the UK, supported by comprehensive sales and distribution networks.

In Asia-Pacific, key markets such as China, Japan, and India benefit from Merck’s local manufacturing and regional offices.

In Latin America, it is active in major markets such as Brazil. While operations in South Africa extend its reach into Africa.

Merck’s global endeavors in research, production, and distribution underscore its commitment to advancing pharmaceutical innovation and accessibility worldwide.  

Recent Developments

  • In January 2024, Merck licensed its CRISPR technology to PanCELLa. A cell therapy firm, and Takara Bio USA, Inc., a biotech company.
  • In June 2022, Merck introduced the Merck Digital Sciences Studio (MDSS) to support cutting-edge technologies in drug discovery and development.


Company Overview

Establishment Year 1973
Headquarter Paris, France
Key Management Paul Hudson (CEO)
Revenue (US$ Bn) $ 50.2 Billion (2022)
Headcount ~ 86,088 (2023)

About Sanofi

Sanofi S.A. has made significant advancements in CRISPR technology, forging key partnerships and initiatives.

In 2024, Sanofi announced a pioneering collaboration with OpenAI and Formation Bio to utilize AI-driven software for accelerating drug development.

This underscores Sanofi’s commitment to integrating cutting-edge technologies. Additionally, Sanofi has entered a strategic partnership with Scribe Therapeutics worth potentially over $1 billion to develop CRISPR-based NK cell therapies for cancer treatment.

This collaboration provides Sanofi access to Scribe’s CRISPR platform. Enhancing its ability to innovate ex vivo NK cell therapies targeting solid tumors and blood cancers.

These efforts illustrate Sanofi’s proactive stance in leveraging CRISPR technology to advance oncology treatments.

Geographical Presence

Sanofi S.A., headquartered in Paris, France, boasts a robust global presence across Europe, North America, Asia-Pacific, Latin America, and the Middle East/Africa.

Key markets include France, Germany, the United States, Japan, China, Brazil, and Saudi Arabia, among others.

This extensive footprint supports Sanofi’s operations in research, manufacturing, and commercial activities. Ensuring strategic alignment with regional healthcare needs and market opportunities worldwide.

Recent Development

  • In May 2024, Sanofi, Formation Bio, and OpenAI teamed up to develop AI-driven software aiming to speed up drug development and enhance the efficiency of delivering new medications to patients.
  • In September 2022, Sanofi and Scribe Therapeutics joined forces to create CRISPR-based cell therapies targeting cancer.


Company Overview

Establishment Year 1958
Headquarter Waltham, Massachusetts, U.S.
Key Management Marc N. Casper (CEO)
Revenue (US$ Bn) $ 42.8 Billion (2023)
Headcount ~ 122,000 (2023)

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is bolstering its role in the CRISPR technology sector through strategic actions and innovations.

By early 2024, the company had achieved strong financial growth and continued to invest in CRISPR technologies.

Thermo Fisher offers a wide array of genome editing solutions, including CRISPR proteins, mRNA, plasmids, and guide RNA (gRNA). Which are essential for diverse gene editing applications such as disease modeling and gene expression.

Recently, Thermo Fisher enhanced its CRISPR workflows by integrating Gibson Assembly. Which simplifies the cloning of large DNA fragments and accelerates tool development.

The company has also pursued acquisitions, like the tender offer for Olink. Aimed at expanding its capabilities in genetic analysis and molecular diagnostics.

These efforts underscore Thermo Fisher’s commitment to advancing CRISPR technology and providing advanced solutions worldwide.

Geographical Presence

Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts, USA, maintains a global presence across North America, Europe, Asia-Pacific, Latin America, and other regions.

The company operates manufacturing facilities, research centers, and offices worldwide. In North America, it has significant operations in the US and Canada.

Europe serves as another major hub, with key activities in the UK, Germany, France, and Switzerland. The company has also expanded in the Asia-Pacific region, including China, Japan, and India, and holds a prominent position in Latin America, notably in Brazil and Mexico.

Thermo Fisher Scientific’s extensive global footprint enables it to lead the global provision of scientific instruments, laboratory equipment, and healthcare solutions, driven by strategic acquisitions and local market expertise.

Recent Development

  • In June 2024, Thermo Fisher Scientific Inc. launched the Thermo Scientific™ Stellar™ mass spectrometer, known for its fast performance, sensitivity, and intuitive design.
  • In June 2024, Thermo Fisher Scientific Inc. launched a new ultra-cold facility in the EU to enhance clinical trial capabilities for advancing therapy development across Europe.


Company Overview

Establishment Year 1887
Headquarter Princeton, New Jersey, U.S.
Key Management Chris Boerner (CEO)
Revenue (US$ Bn) $ 45.01 B (2023)
Headcount ~ 34,100 (2023)

About Bristol Myers Squibb

Bristol Myers Squibb (BMS) is actively expanding its presence in CRISPR technology, focusing on advanced cellular therapies.

The company has partnered notably with Century Therapeutics to develop gene-edited iPSC-derived therapies for acute myeloid leukemia (AML) and multiple myeloma.

Recently, BMS acquired Karuna Therapeutics to enrich its pipeline with new therapeutic candidates. Furthermore, BMS has entered a $380 million agreement with Cellares to enhance the manufacturing of CAR T cell therapies globally.

These strategic moves highlight BMS’s commitment to harnessing CRISPR technology for cutting-edge treatments in both hematological and solid tumors.

Geographical Presence

Bristol Myers Squibb (BMS), headquartered in New York City, is a leading global biopharmaceutical company with operations across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

In North America, BMS operates extensive research and manufacturing facilities, while in Europe, it conducts R&D in key markets like France, Germany, and the UK. Across Asia-Pacific, including Japan and China, BMS focuses on clinical trials and commercial operations.

In Latin America, BMS collaborates to improve healthcare access, and in the Middle East and Africa, it supports healthcare advancements, notably in South Africa and Saudi Arabia. This strategy underscores BMS’s commitment to innovation and enhancing global patient outcomes.

Recent Developments

  • In March 2024, Bristol Myers Squibb’s Breyanzi, a CAR T cell therapy directed at CD19, was FDA-approved for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior systemic therapies, including treatment with a Bruton tyrosine kinase (BTK) inhibitor.
  • In February 2024, Bristol Myers Squibb finalized its acquisition of RayzeBio, Inc.


Company Overview

Establishment Year 1901
Headquarter Tel Aviv, Israel
Key Management Richard Francis (President and CEO)
Revenue (US$ Bn) $ 15.8 Billion (2023)
Headcount ~ 35,000 (2023)

About Teva Pharmaceuticals

Teva Pharmaceuticals is actively involved in advancing CRISPR technology for drug development, integrating artificial intelligence and other advanced tools to streamline research processes.

Their use of CRISPR-Cas9 for precise genome editing is poised to expedite the creation of new therapies. Throughout 2023, Teva engaged in collaborative research projects targeting genetic disorders, underscoring its commitment to pharmaceutical innovation.

These initiatives are part of Teva’s strategy to enhance the efficiency and effectiveness of its drug discovery and development efforts while maintaining leadership in the industry.

Geographical Presence

Teva Pharmaceuticals, based in Israel, has a robust global presence spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.

It is a leading provider of generic pharmaceuticals in North America with extensive manufacturing capabilities.

In Europe, Teva holds significant market positions in the UK, Germany, and France, supported by its Amsterdam headquarters.

In Asia-Pacific, the company focuses on Japan, Australia, India, and China while also expanding across Latin America.

Its operations in the Middle East/Africa cover Israel, South Africa, and Turkey, bolstered by local partnerships.

Teva’s extensive network of manufacturing sites and distribution centers ensures efficient global supply chain management, facilitating the widespread availability of its pharmaceutical products.  

Recent Developments

  • In April 2024, Teva Pharmaceuticals reported positive findings from the Phase 4 START study’s HD cohort, showing favorable real-world results in effectiveness, safety, adherence, and satisfaction with the 4-week Titration Kit for AUSTEDO.
  • In April 2024, Teva Pharmaceuticals and mAbxience, primarily owned by Fresenius Kabi and partly by Insud Pharma, signed a strategic licensing agreement for a biosimilar in development for oncology treatments.


Company Overview

Establishment Year 1896
Headquarter Basel, Switzerland
Key Management Thomas Schinecker (CEO)
Revenue (US$ Bn) $ 65.4 Billion (2022)
Headcount ~ 122,000 (2022)

About Roche

Roche is actively advancing its biopharmaceutical R&D through CRISPR technology, engaging in strategic initiatives and partnerships aimed at developing CRISPR-based therapies for genetic disorders.

Recently, Roche opened new research facilities dedicated to gene editing, enhancing their capabilities in genomic technologies.

They are actively involved in clinical trials for conditions such as sickle cell disease, underscoring their commitment to pioneering next-generation treatments and remaining a leader in genetic research.

Geographical Presence

Headquartered in Basel, Switzerland, Roche is a global leader in pharmaceuticals and diagnostics. The company operates extensively across Europe, with major facilities in Germany, France, Italy, and the UK.

In North America, Roche has significant operations in the US, including hubs in South San Francisco and Indianapolis, and also operates in Canada.

Roche has established strong footholds in Japan, China (Shanghai, Beijing), and across India and Southeast Asia in the Asia-Pacific region.

In Latin America, Roche serves markets like Brazil and maintains operations in South Africa and other parts of the Middle East and Africa.

This extensive global presence highlights Roche’s dedication to advancing healthcare through innovative solutions worldwide.

Recent Developments

  • In December 2021, Roche launched the AVENIO Edge System to enhance its sequencing technology capabilities.
  • In August 2021, Roche’s FDA approval of the VENTANA MMR RxDx Panel highlighted its commitment to personalized healthcare by identifying patients eligible for targeted therapies.


Company Overview

Establishment Year 1849
Headquarter New York City, U.S.
Key Management Albert Bourla (CEO)
Revenue (US$ Bn) $ 58.5 Billion (2023)
Headcount ~ 88,000 (2023)

About Pfizer

Pfizer Inc. has expanded its role in CRISPR technology through investments and partnerships. In 2023, Pfizer invested $25 million in Caribou Biosciences to advance CRISPR therapies for multiple myeloma, demonstrating its commitment to gene editing in oncology.

Pfizer also began a four-year research collaboration with Beam Therapeutics valued at up to $1.35 billion, focusing on in vivo base editing for rare genetic disorders.

The acquisition of Seagen in December 2023 has strengthened Pfizer’s oncology portfolio by incorporating CRISPR technology, particularly in developing advanced cancer treatments like antibody-drug conjugates.

Pfizer is also collaborating with UT Southwestern Medical Center on RNA delivery technologies to expand its capabilities in genetic medicine. These efforts underscore Pfizer’s strategic focus on innovation to address critical medical needs.

Geographical Presence

Pfizer Inc., headquartered in New York, maintains a strong global presence across North America, Europe (including major markets such as the UK, Germany, and France), Asia-Pacific (including Japan, China, and India), Latin America (especially in Brazil, Mexico, and Argentina), and the Middle East/Africa (including South Africa and Gulf region partnerships).

The company is actively engaged in manufacturing, research, and commercial operations in these regions, emphasizing its dedication to global healthcare through extensive research and development, pharmaceutical manufacturing, and a robust distribution infrastructure.

Recent Development

  • In February 2024, Pfizer teamed up with UT Southwestern Medical Center’s Dallas-based Program in Genetic Drug Engineering to develop RNA-enhanced delivery technologies for genetic medicine therapies.
  • In July 2023, Pfizer invested $25 million in Caribou Biosciences, signaling confidence and providing funding for an experimental treatment for multiple myeloma using gene editing.


Company Overview

Establishment Year 1984
Headquarter Venlo, Netherlands
Key Management Thierry Bernard (CEO)
Revenue (US$ Bn) $ 1.9 Billion (2023)
Headcount ~ 5,967 (2023)

About Qiagen

Qiagen NV has bolstered its position in the CRISPR technology sector with recent product launches and strategic financial initiatives.

The company introduced the QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions, designed to streamline gene-editing experiments by combining liquid-based sample preparation with PCR detection and Sanger sequencing. These innovations promise faster results and improved efficiency in CRISPR research.

Additionally, Qiagen announced plans to return up to $300 million to shareholders through a synthetic share repurchase program aimed at boosting earnings per share (EPS) and demonstrating strong financial stewardship and shareholder value commitment.

Geographical Presence

Qiagen NV, a leading player in the life sciences and molecular diagnostics industry, maintains a global presence with strategic operations across key regions.

Headquartered in Germantown, Maryland, USA, and Hilden, Germany, Qiagen operates manufacturing facilities, distribution centers, and sales offices worldwide.

In North America, it serves from its US and Canadian bases, while in Europe, it has a strong foothold in Germany, the UK, and the Netherlands.

Qiagen also addresses the Asia-Pacific market through offices in China, Japan, and India, focusing on expanding its molecular testing solutions.

Additionally, it operates in Brazil to cater to the Latin American market, utilizing a comprehensive distribution and sales network to ensure efficient service delivery globally.

Recent Developments

  • In January 2024, QIAGEN announced its intention to execute a synthetic share repurchase, intending to return about $300 million to shareholders through a mix of direct capital repayment and a reverse stock split.
  • In June 2021, QIAGEN launched the QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions for rapid and efficient analysis of edited genetic material.


Company Overview

Establishment Year 1994
Headquarter Chicago, Illinois, U.S.
Key Management Peter Arduini (CEO)
Revenue (US$ Bn) $ 19.5 Billion (2023)
Headcount ~ 51,000 (2023)

About GE Healthcare

GE Healthcare has advanced in CRISPR technology, enhancing gene editing and diagnostics with new tools for more accurate applications. Innovations like real-time imaging systems monitor CRISPR edits, which is crucial for precise procedures.

Through strategic partnerships with research institutions, GE Healthcare develops CRISPR-based diagnostics and therapies for oncology and genetic disorders, integrating these technologies to advance molecular diagnostics and personalized medicine capabilities.

Geographical Presence

GE Healthcare is widely present across North America, Europe, Asia-Pacific, Latin America, and the Middle East.

In North America, it offers advanced medical imaging and healthcare IT solutions for the US and Canadian markets.

Europe benefits from GE Healthcare’s diverse array of diagnostic imaging and biopharmaceutical manufacturing technologies.

In Asia-Pacific, including major markets like China and India, GE Healthcare meets growing healthcare needs with innovative medical technologies and precision medicine solutions.

Latin America and the Middle East also benefit from GE Healthcare’s advanced healthcare solutions, enhancing clinical outcomes and operational efficiency across diverse healthcare settings.

Recent Developments

  • In May 2024, GE Healthcare collaborated with Medis Medical Imaging to improve diagnostic accuracy and treatment of coronary artery disease.
  • In February 2024, GE Healthcare partnered with Biofourmis to extend care continuity through safe, effective, and accessible home-based services, broadening support beyond hospital settings.


Leave a Reply

Your email address will not be published. Required fields are marked *